Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images

BACKGROUND: Currently, only a fraction of patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) experience a durable clinical benefit (DCB). According to NCCN guidelines, Programmed death-ligand 1 (PD-L1) expression status determined by immunohistochemistr...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Wei, Jiang, Lei, Shi, Yu, Tunali, Ilke, Gray, Jhanelle E, Katsoulakis, Evangelia, Tian, Jie, Gillies, Robert J, Schabath, Matthew B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211060/
https://www.ncbi.nlm.nih.gov/pubmed/34135101
http://dx.doi.org/10.1136/jitc-2020-002118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211060/
https://www.ncbi.nlm.nih.gov/pubmed/34135101
http://dx.doi.org/10.1136/jitc-2020-002118

Ejemplares similares